Largest pharmaceutical companies by total debt
Borrowings at the end of the latest fiscal year: long-term debt including the part due within a year, plus short-term borrowings. Leases are left out unless the company reports them in one figure with its debt.
AbbVie leads the 35 pharmaceutical companies ranked by total debt, at SAR 253.2B, ahead of Pfizer (SAR 243B) and Merck & Co (SAR 184.9B). Figures as of 18 Nov 2026, 19:33 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 35
- First
- AbbVieSAR 253.2B
- Median
- SAR 19.8B
- Combined market value
- SAR 18.98T
- Countries
- 10
- Not ranked
- 26no total debt on file
Market values as of .
All countries▾
All sectors▾
Pharmaceuticals▾
| # | Company | Total debt ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AbbVieABBV · Health Care | SAR 253.2B | SAR 1.89T | SAR 1,071.15 | 2.48% down | 26% up | ||
| 2 | PfizerPFE · Health Care | SAR 243B | SAR 599.5B | SAR 105.18 | 1.51% down | 14% up | ||
| 3 | Merck & CoMRK · Health Care | SAR 184.9B | SAR 1.27T | SAR 515.07 | 4.22% down | 51% up | ||
| 4 | Johnson & JohnsonJNJ · Health Care | SAR 179.8B | SAR 2.47T | SAR 1,025.92 | 1.86% down | 38% up | ||
| 5 | Bristol-Myers SquibbBMY · Health Care | SAR 169.2B | SAR 457B | SAR 223.56 | 2.85% down | 34% up | ||
| 6 | Eli LillyLLY · Health Care | SAR 159.4B | SAR 4.62T | SAR 5,190.77 | 2.24% down | 35% up | ||
| 7 | Takeda PharmaceuticalTAK · Health Care | SAR 114.7B | SAR 255B | SAR 79.82 | 1.66% down | 54% up | ||
| 8 | AstraZenecaAZN · Health Care | SAR 111.1B | SAR 1.04T | SAR 669.63 | 2.06% down | 2% up | ||
| 9 | NovartisNVS · Health Care | SAR 107.8B | SAR 1.1T | SAR 581.71 | 2.55% down | 25% up | ||
| 10 | SanofiSNY · Health Care | SAR 77.8B | SAR 425.1B | SAR 177.03 | 0.70% down | 4% down | ||
| 11 | Novo NordiskNVO · Health Care | SAR 72.9B | SAR 651.3B | SAR 147.77 | 3.21% down | 17% down | ||
| 12 | GSKGSK · Health Care | SAR 72B | SAR 365.4B | SAR 182.32 | 1.29% down | 6% up | ||
| 13 | ViatrisVTRS · Health Care | SAR 54.1B | SAR 88.5B | SAR 77.21 | 0.66% up | 96% up | ||
| 14 | Abbott LaboratoriesABT · Health Care | SAR 48.5B | SAR 679B | SAR 392.02 | 0.19% down | 17% down | ||
| 15 | ZoetisZTS · Health Care | SAR 33.9B | SAR 130.1B | SAR 320.25 | 2.27% up | 29% down | ||
| 16 | Royalty PharmaRPRX · Health Care | SAR 33.6B | SAR 149.6B | SAR 260.11 | 0.97% up | 78% up | ||
| 17 | Jazz PharmaceuticalsJAZZ · Health Care | SAR 20.1B | SAR 59.2B | SAR 921.85 | 2.10% up | 37% up | ||
| 18 | GenmabGMAB · Health Care | SAR 19.8B | SAR 118.6B | SAR 192.39 | 1.29% down | 70% up | ||
| 19 | Elanco Animal HealthELAN · Health Care | SAR 15.1B | SAR 50.3B | SAR 100.71 | 3.87% up | 20% up | ||
| 20 | Amneal PharmaceuticalsAMRX · Health Care | SAR 9.6B | SAR 28.5B | SAR 81.81 | 3.27% up | 83% up | ||
| 21 | BridgeBio PharmaBBIO · Health Care | SAR 7.5B | SAR 56.7B | SAR 291.25 | 1.10% up | 17% up | ||
| 22 | Regeneron PharmaceuticalsREGN · Health Care | SAR 7.4B | SAR 366.6B | SAR 3,543.76 | 1.36% down | 36% up | ||
| 23 | Ionis PharmaceuticalsIONS · Health Care | SAR 6.8B | SAR 17.3B | SAR 103.68 | 2.52% up | 64% down | ||
| 24 | BeOne MedicinesONC · Health Care | SAR 3.9B | SAR 173.2B | SAR 1,515.97 | 2.20% down | 17% up | ||
| 25 | Ascendis PharmaASND · Health Care | SAR 3B | SAR 66.4B | SAR 1,011.72 | 0.54% down | 28% up | ||
| 26 | InsmedINSM · Health Care | SAR 2.1B | SAR 98.9B | SAR 450.65 | 1.41% down | 40% down | ||
| 27 | Madrigal PharmaceuticalsMDGL · Health Care | SAR 1.3B | SAR 35B | SAR 1,506.76 | 4.81% down | 24% down | ||
| 28 | Legend BiotechLEGN · Health Care | SAR 1.2B | SAR 11.8B | SAR 60.62 | 0.31% up | 42% down | ||
| 29 | CytokineticsCYTK · Health Care | SAR 1.1B | SAR 26.7B | SAR 191.94 | 0.93% down | 20% down | ||
| 30 | TG TherapeuticsTGTX · Health Care | SAR 921.4M | SAR 37.2B | SAR 246.40 | 4.75% up | 107% up | ||
| 31 | Cogent BiosciencesCOGT · Health Care | SAR 836.1M | SAR 18.3B | SAR 105.37 | 0.86% up | 20% down | ||
| 32 | Dr. Reddy's LaboratoriesRDY · Health Care | SAR 726.7M | SAR 46.9B | SAR 56.21 | 1.32% up | 5% up | ||
| 33 | Axsome TherapeuticsAXSM · Health Care | SAR 704.2M | SAR 26.5B | SAR 503.42 | 1.28% down | 7% down | ||
| 34 | Rhythm PharmaceuticalsRYTM · Health Care | SAR 405.8M | SAR 31.2B | SAR 450.53 | 3.00% up | 13% up | ||
| 35 | Definium TherapeuticsDFTX · Health Care | SAR 152.2M | SAR 14.7B | SAR 107.24 | 2.69% down | 169% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Total debt is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Total debt is assembled from each company's debt lines and is the least complete of these figures: some companies tag part of their borrowings in ways it misses. Sums are converted from US dollars at today's exchange rate (1 USD = 3.7510 SAR). 26 companies have no total debt on file and are not ranked here.
Questions and answers
Which pharmaceutical companies rank first by total debt?
AbbVie (SAR 253.2B), Pfizer (SAR 243B) and Merck & Co (SAR 184.9B) are the top three of the 35 pharmaceutical companies ranked by total debt as of 18 Nov 2026, 19:33 UTC.
How many pharmaceutical companies are in this ranking?
35 are ranked by total debt. 26 more have no total debt on file and are left out rather than ranked at zero.
What are these pharmaceutical companies worth together?
The 35 pharmaceutical companies ranked by total debt have a combined market value of SAR 18.98T as of 18 Nov 2026, 19:33 UTC.
What does ranking by total debt measure?
Borrowings at the end of the latest fiscal year: long-term debt including the part due within a year, plus short-term borrowings. Leases are left out unless the company reports them in one figure with its debt.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest pharmaceutical companies by total debt”, data as of 18 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?by=total-debt
Underlying data: Yahoo Finance; SEC EDGAR.